Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Treasurer of the State of North Carolina

Treasurer of the State of North Carolina raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIVFree Report) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 157,830 shares of the company’s stock after purchasing an additional 5,190 shares during the quarter. Treasurer of the State of North Carolina’s holdings in Roivant Sciences were worth $1,772,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ROIV. Mirabella Financial Services LLP increased its stake in Roivant Sciences by 4.1% during the 3rd quarter. Mirabella Financial Services LLP now owns 34,583 shares of the company’s stock worth $404,000 after buying an additional 1,362 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Roivant Sciences by 42.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company’s stock worth $60,000 after acquiring an additional 1,608 shares during the period. VELA Investment Management LLC raised its holdings in shares of Roivant Sciences by 8.8% during the fourth quarter. VELA Investment Management LLC now owns 32,386 shares of the company’s stock valued at $364,000 after buying an additional 2,621 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in Roivant Sciences during the 4th quarter valued at $33,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Roivant Sciences in the 4th quarter worth approximately $36,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ROIV. Wolfe Research began coverage on Roivant Sciences in a research report on Thursday, February 15th. They set an “outperform” rating and a $17.00 price objective for the company. TheStreet raised shares of Roivant Sciences from a “d” rating to a “c+” rating in a research note on Tuesday, February 13th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Friday, May 31st. Deutsche Bank Aktiengesellschaft lifted their target price on Roivant Sciences from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, The Goldman Sachs Group boosted their price objective on shares of Roivant Sciences from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus price target of $16.90.

Get Our Latest Stock Report on ROIV

Roivant Sciences Stock Down 1.4 %

Shares of ROIV stock opened at $10.47 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 25.24 and a current ratio of 25.24. The stock’s 50 day simple moving average is $11.03 and its 200 day simple moving average is $10.75. The company has a market capitalization of $8.44 billion, a price-to-earnings ratio of 2.07 and a beta of 1.25. Roivant Sciences Ltd. has a twelve month low of $8.24 and a twelve month high of $13.24.

About Roivant Sciences

(Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Read More

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIVFree Report).

Institutional Ownership by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.